Biomea Fusion Inc. has prepared new fused pyrimidine compounds acting as menin (MEN1)/KMT2A (MLL) interaction inhibitors. They are reported to be potentially useful for the treatment of cancer, ...

Copyright held by the owner/author(s).

Beijing Key Laboratory of Active Substances Discovery and Druggability Evaluation, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, ...

Department of Biochemistry and Molecular Biology, Saint Louis University School of Medicine, Saint Louis, Missouri 63104, United States Institute for Drug and Biotherapeutic Innovation, Saint Louis ...

Cancer cells must have access to pyrimidine supplies to produce more cancer cells and to produce uridine nucleotides, a primary fuel source for cancer cells as they rapidly reproduce, grow, and die.

Azacitidine is under clinical development by Bristol-Myers Squibb and currently in Phase II for Essential Thrombocythemia.

Azacitidine is under clinical development by Bristol-Myers Squibb and currently in Phase II for Polycythemia Vera.

Differentiated thyroid cancers (DTC) and anaplastic thyroid cancers (ATC) often develop primary and acquired resistance to standard treatments. This highlights the need for new therapeutic strategies ...

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH – Get Free Report)’s share price fell 0.7% on Wednesday . The company traded as low as $0.61 and last traded at $0.61. 40,294 shares were traded ...